GlassScriptPhysician profile
Joshua Max
NPI 1174729438
$25,959.56
in general payments reported to CMS, 2019-2025
33 companies · $3,632 in 2025
The $3,632 reported for 2025 was more than what 89% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $208 · 2020: $87.46 · 2021: $682 · 2022: $1,628 · 2023: $1,333 · 2024: $18K · 2025: $3,632.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $17K · Food and Beverage: $5,519 · Travel and Lodging: $1,066.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $16,770.00 |
| Food and Beverage | $5,518.51 |
| Travel and Lodging | $1,065.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $18,881.78 | 2024-2025 | Voquezna |
| Abbvie INC. | $2,302.98 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $589.02 | 2019-2024 | Entyvio, Eohilia, Gattex |
| Regeneron Healthcare Solutions, INC. | $468.43 | 2022-2025 | Dupixent |
| Celgene Corporation | $371.47 | 2022-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $370.30 | 2019-2024 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $301.10 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Boston Scientific Corporation | $278.17 | 2022-2025 | Axios |
| Janssen Scientific Affairs, LLC | $259.06 | 2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $236.97 | 2021-2022 | |
| Genzyme Corporation | $226.05 | 2022-2025 | |
| Pfizer INC. | $200.00 | 2022-2025 | |
| Steris Corporation | $197.60 | 2024 | |
| Gilead Sciences, INC. | $174.91 | 2021-2025 | |
| Aimmune Therapeutics, INC. | $172.09 | 2025 | Zenpep |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $142.23 | 2024-2025 | Iqirvo, Bylvay |
| Redhill Biopharma INC. | $138.19 | 2020-2021 | |
| Ardelyx, INC. | $107.00 | 2022-2025 | Ibsrela |
| Daiichi Sankyo INC. | $78.03 | 2022 | |
| Ferring Pharmaceuticals INC. | $72.75 | 2023-2025 | Rebyota |
| Madrigal Pharmaceuticals | $61.56 | 2025 | Rezdiffra |
| Braintree Laboratories, INC. | $53.37 | 2021-2025 | Sutab, Suflave |
| Lilly USA, LLC | $49.70 | 2024-2025 | Omvoh |
| Cook Medical LLC | $42.66 | 2024-2025 | Hemospray |
| Nestle Healthcare Nutrition INC. | $31.04 | 2021-2022 | |
| Novo Nordisk INC | $29.58 | 2025 | Wegovy |
| Ironwood Pharmaceuticals, INC | $24.61 | 2021-2022 | |
| Qol Medical, LLC | $21.54 | 2022 | |
| Azurity Pharmaceuticals, INC. | $17.77 | 2025 | Sutab |
| Apollo Endosurgery US INC | $16.45 | 2022 | |
| Evoke Pharma, INC. | $15.19 | 2024 | |
| Intercept Pharmaceuticals, INC. | $14.51 | 2024 | |
| Organon LLC | $13.45 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joshua Max listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.